Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Change in Receivables for 4 consecutive years, with $43000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 213.16% to $43000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2025, up 113.64% year-over-year, with the annual reading at $3000.0 for FY2025, 113.64% up from the prior year.
  • Change in Receivables for Q4 2025 was $43000.0 at Orchestra BioMed Holdings, up from -$31000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $95000.0 in Q2 2023, with the low at -$85000.0 in Q3 2023.
  • Average Change in Receivables over 4 years is -$2733.3, with a median of -$3000.0 recorded in 2025.
  • Peak annual rise in Change in Receivables hit 9400.0% in 2023, while the deepest fall reached 631.25% in 2023.
  • Over 4 years, Change in Receivables stood at $16000.0 in 2022, then dropped by 18.75% to $13000.0 in 2023, then crashed by 392.31% to -$38000.0 in 2024, then skyrocketed by 213.16% to $43000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $43000.0, -$31000.0, and -$6000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.